Zhu Yi

🇨🇳 Zhu Yi

💊 From immunology lecturer to pharma pioneer: Zhu Yi, chairman of Chengdu-based Biokin Pharmaceutical, took the company public in Shanghai in 2023 and, via U.S. subsidiary SystImmune, inked an $8.4B licensing deal with Bristol Myers Squibb for a new cancer therapy. The market is moving the same way: U.S. biotechs are adding China-developed assets to their pipelines and pushing global development. Today, Zhu’s net worth stands at $12.4B.

👉 Lesson learned: “Made in China, scaled in the U.S.” is the new biotech playbook. Leverage China’s speed and cost advantages, then pursue validation, approvals, and capital on global markets.